ESMO Annual Congress Coverage
The European Society for Medical Oncology annual congress for 2024 takes place in Barcelona, Spain from 13-17 September. This page is your one-stop shop for all of Scrip's conference coverage, including preview and post-meeting analysis. You can also find archive content from previous meetings here.
![](/-/media/editorial/scrip/2024/09/sc2409_barcelona_2431071037_1200.jpg?rev=17f3916792d346ecb5c9e09529642d37&w=350&hash=7278D69AF600AB8AB8047741A1397DC1)
What To Look Out For At ESMO 2024
Attendees at this year's European Society for Medical Oncology meeting in Barcelona can look forward to a range of interesting datasets, from Phase III trials of established products in new settings to preliminary studies of novel products coming through the pipeline.
![](/-/media/editorial/hbw-insight/hbw-stock-images/ppp_money_687049846_1200.jpg?rev=9b798f7345ff42bfb038e14d38769ab8&w=350&hash=ECFF237A5D2FFE9BD953D1A7FD3D0BC1)
Arcus Borrows $250m Despite Having $1bn In The Bank
A loan from Hercules Capital will fund Phase III development of renal cancer drug casdatifan, perhaps signaling low expectations of a Gilead opt-in.
![](/-/media/editorial/stock-images/cells/tcells-attack-cancer_1331794052_1200.jpg?rev=24235da85db649c4a5818b5b8fbfe342&w=350&hash=B3F6C469FED7F6350947ADCA717DB43C)
Immutep LAG-3 Inhibitor May Have Path Forward
After missing statistical significance in PD-L1+ head-and-neck cancer, Immutep presents data showing eftilagimod with Keytruda can offer efficacy in PD-L1-negative patients.
![](/-/media/editorial/scrip/00_regular-column-images/pipeline_watch_option_2_cbamnw_1200.jpg?rev=849ef614e1af489bb0079b53fe950e1a&w=350&hash=60E34E571A0E1881A27271D99D8E00B4)
Pipeline Watch: 11 Approvals And Two Phase III Readouts
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
![](/-/media/editorial/scrip/00_regular-column-images/pipeline_watch_option_2_cbamnw_1200.jpg?rev=849ef614e1af489bb0079b53fe950e1a&w=350&hash=60E34E571A0E1881A27271D99D8E00B4)
Pipeline Watch: 23 Approvals And 14 Phase III Readouts
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
![](/-/media/editorial/scrip/2022/12/sc2212_china_pharma_us_trial_1784185820_1200.jpg?rev=26c21592875b4b7aa254018c5d9c894f&w=350&hash=17150AE1A07179590A8C523C9CD04C20)
China Approval For Akeso’s Bispecific But ASCO Data Unnerve Investors
Ivonescimab in combination with chemotherapy reduced the risk of disease progression or death by 54% versus placebo in EGFR-mutated, non-squamous NSCLC after failed EGFR inhibitor treatment. However, the progression-free survival data did little to satisfy investors’ demand for clear benefits versus competitors.
![](/-/media/editorial/stock-images/diseases/lungcancer_47781766_1200.jpg?rev=74a714f24e7d47119792e90af99c7258&w=350&hash=CDBCEBD193AEF8453156926425B9FFCA)
AstraZeneca And Daiichi Follow Gilead’s Lead
The partners’ antibody-drug conjugate datopotamab deruxtecan misses on overall survival, potentially limiting its market reach.
![](/-/media/editorial/stock-images/policy_regulation/sc2405_fdaapproval_1744487396_1200.jpg?rev=540446240cf747638ef12a242dc91453&w=350&hash=8887AD470505D4FDB8365448BCDC8679)
Amgen’s Imdelltra Wins FDA Nod In Underserved SCLC Population
The DLL3-targeting bispecific antibody won accelerated approval in extensive-stage small-cell lung cancer among patients treated with platinum chemotherapy.
![](/-/media/editorial/scrip/00_regular-column-images/pipeline_watch_option_2_cbamnw_1200.jpg?rev=849ef614e1af489bb0079b53fe950e1a&w=350&hash=60E34E571A0E1881A27271D99D8E00B4)
Pipeline Watch: Six Approvals And 12 Phase III Readouts
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
![](/-/media/editorial/stock-images/pharma_medication/fdaapprovalcertification_bakhtiarzein_382445539_1200.jpg?rev=62ca53b471ff4435b8be497d0c19d53a&w=350&hash=2CC19C8326B076D949E9836408D9F4E5)
Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval
The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.
![](/-/media/editorial/scrip/00_regular-column-images/pipeline_watch_option1_tadra4_1200.jpg?rev=394d0068fb114e4eb545fd74cd77e1ed&w=350&hash=1DA252FD641196A60C6F984DF4C84814)
Pipeline Watch: Four Approvals And 21 Phase III Trial Updates
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
![](/-/media/editorial/scrip/2024/01/sc2401_sp_target_320549678_1200.jpg?rev=a579239bad034bf99f57e80fb279c771&w=350&hash=C0B4BE093A8090EA1538CAFCF17F00BA)
Five Clinical Trial Hits Of 2023
The biopharma industry’s fate lies largely in its R&D successes and failures. Here, Scrip looks at five clinical trial successes that will shape their sponsors’ futures and got readers clicking in 2023.
![](/-/media/editorial/scrip/2022/11/sc2211_acquisition_1365692276_1200.jpg?rev=ef76166959f64860b6ff78ebd69461e9&w=350&hash=FE96491AD4AE9A34834B18A63C733B55)
BMS Bets $8.4bn On Biokin’s Bispecific ADC
In a record licensing deal involving a single biopharma asset from China, Biokin and its US subsidiary SystImmune will receive up to $8.4bn from BMS, including $800m upfront, for a bispecific ADC with broad oncology potential.
![](/-/media/editorial/scrip/00_regular-column-images/pipeline_watch_option_2_cbamnw_1200.jpg?rev=849ef614e1af489bb0079b53fe950e1a&w=350&hash=60E34E571A0E1881A27271D99D8E00B4)
Pipeline Watch: 10 Approvals And 22 Phase III Trial Updates
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
![](/-/media/editorial/stock-images/diseases/breastcancerdocwithmammography_289309193_1200x675.jpg?rev=f5636b7ff9d547ca85eac706f6a36b46&w=350&hash=50975CD8F20CA5443C90806F5F1388AA)
Olema Boosts Its Partnering Position With SERD Combo Data
Scrip caught up with Olema CEO Sean Bohen ahead of a crucial combination data readout due this month for its novel SERD, palazestrant, which it hopes will put the drug on the path to a $10bn-plus breast cancer market.
![](/-/media/editorial/scrip/2023/11/sc2311_purplefdaapproved_363500174_1200.jpg?rev=a175a676e4f64446a3b5ba05ee736270&w=350&hash=CD9D28CEFB6D725DCF2FCF35DC5E4090)
SpringWorks’ Ogsiveo Is First-Ever US FDA-Approved Drug For Desmoid Tumors
SpringWorks’ gamma secretase inhibitor will be available soon for adults at any stage of treatment for desmoid tumors with a list price of $29,000 for a 30-day supply.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.